| KESGX | NAESX | KESGX / NAESX | |
| Total Expense Ratio | 0.82 | 0.17 | 482% |
| Annual Report Gross Expense Ratio | 1.08 | 0.17 | 635% |
| Fund Existence | 7 years | 66 years | - |
| Gain YTD | 21.081 | 14.563 | 145% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 5000 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 92.2M | 189B | 0% |
| Annual Yield % from dividends | 0.22 | 1.10 | 20% |
| Returns for 1 year | 22.05 | 22.56 | 98% |
| Returns for 3 years | 44.35 | 43.30 | 102% |
| Returns for 5 years | 31.72 | 34.95 | 91% |
| Returns for 10 years | N/A | 155.28 | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| VMMSX | 32.15 | 0.39 | +1.23% |
| Vanguard Emerg Mkts Sel Stk Inv | |||
| VRGWX | 936.97 | 7.54 | +0.81% |
| Vanguard Russell 1000 Growth Index I | |||
| GIDWX | 20.04 | 0.13 | +0.65% |
| Goldman Sachs US Eq Div and Premium R6 | |||
| CAVAX | 18.71 | 0.04 | +0.21% |
| SEI Catholic Values Equity F (SCVT) | |||
| RYOIX | 86.56 | -2.00 | -2.26% |
| Rydex Biotechnology Inv | |||